Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics

Eledon Pharmaceuticals, Inc. (ELDN): $1.88

0.06 (+3.30%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add ELDN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#224 of 349

in industry

ELDN Price/Volume Stats

Current price $1.88 52-week high $2.95
Prev. close $1.82 52-week low $1.07
Day low $1.80 Volume 25,600
Day high $1.88 Avg. volume 59,278
50-day MA $1.73 Dividend yield N/A
200-day MA $1.54 Market Cap 45.49M

ELDN Stock Price Chart Interactive Chart >


Eledon Pharmaceuticals, Inc. (ELDN) Company Bio


Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.


ELDN Latest News Stream


Event/Time News Detail
Loading, please wait...

ELDN Latest Social Stream


Loading social stream, please wait...

View Full ELDN Social Stream

Latest ELDN News From Around the Web

Below are the latest news stories about ELEDON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELDN as an investment opportunity.

Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | December 25, 2023

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that on December 1, 2023, the Company’s Compensation Committee granted our new Chief Medical Officer, Eliezer Katz, M.D., inducement stock options to purchase an aggregate of 921,000 common shares, at a per share exercise price of $1.14, the closing price of Eledon’s common stock on December 1, 2023. The stock options were granted as inducements material to the new employee en

Yahoo | December 4, 2023

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: The Organ Transplant Revolution, that will take place on Monday, December 4, 20

Yahoo | November 29, 2023

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its third quarter operating and financial

Yahoo | November 9, 2023

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies London Healthcare Conference on Thursday, November 16, 2023, at 8:00 a.m. GMT (3:00 a.m. EST). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on the Events page of the Investors

Yahoo | November 8, 2023

Read More 'ELDN' Stories Here

ELDN Price Returns

1-mo 3.30%
3-mo 56.67%
6-mo 29.66%
1-year -18.61%
3-year -88.61%
5-year N/A
YTD 4.44%
2023 -21.05%
2022 -48.30%
2021 -71.36%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!